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Abstract
Background: Major depressive disorder afflicts an estimated 17% of individuals during their lifetimes at tremendous
suffering and costs. Interpersonal psychotherapy and other psychodynamic therapies may be effective interventions for
major depressive disorder, but the effects have only had limited assessment in systematic reviews.
Methods/Principal Findings: Cochrane systematic review methodology with meta-analysis and trial sequential analysis of
randomized trials comparing the effect of psychodynamic therapies versus ‘treatment as usual’ for major depressive
disorder. To be included the participants had to be older than 17 years with a primary diagnosis of major depressive
disorder. Altogether, we included six trials randomizing a total of 648 participants. Five trials assessed ‘interpersonal
psychotherapy’ and only one trial assessed ‘psychodynamic psychotherapy’. All six trials had high risk of bias. Meta-analysis
on all six trials showed that the psychodynamic interventions significantly reduced depressive symptoms on the 17-item
Hamilton Rating Scale for Depression (mean difference 23.12 (95% confidence interval 24.39 to 21.86;P,0.00001), no
heterogeneity) compared with ‘treatment as usual’. Trial sequential analysis confirmed this result.
Discussion: We did not find convincing evidence supporting or refuting the effect of interpersonal psychotherapy or
psychodynamic therapy compared with ‘treatment as usual’ for patients with major depressive disorder. The potential
beneficial effect seems small and effects on major outcomes are unknown. Randomized trials with low risk of systematic
errors and low risk of random errors are needed.
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Introduction
According to the WHO, major depressive disorder is the second
largest healthcare problem worldwide in terms of illness induced
disability [1]. Major depressive disorder afflicts an estimated 17%
of individuals during their lifetimes at tremendous costs to the
individual and society [2,3], and roughly a third of all depressive
disorders take a chronic course [4,5]. Compared to other medical
disorders, depressive illness causes the most significant deteriora-
tion in individual life quality [6]. Approximately 15% of depressive
patients will commit suicide over a 10–20 year period [7].
Antidepressant medication remains the mainstay in the
treatment of depression [8]. However, meta-analyses have shown
that the new antidepressants only obtained beneficial effect in
severely depressed patients and that this effect was clinically small
[9,10]. Antidepressants are, however, known to decrease the risk of
relapse [11]. The benefits of antidepressant medication seem to be
limited and this raises the question if there are other effective
treatments for this serious illness?
Psychodynamic therapies origin back to Freud [12]. In some
health-care systems it is currently the most commonly used form of
psychotherapy [13]. Interpersonal psychotherapy is generally
considered as one of the most evidence-based therapies for
depression [13]. Interpersonal psychotherapy originates from
classical psychodynamic therapy [14], and although interpersonal
psychotherapy has integrated elements from other psychotherapies
it is generally regarded as a contemporary form of psychodynamic
therapy [14,15]. We have only been able to identify one relevant
meta-analysis examining the effects of psychodynamic therapies
versus ‘treatment as usual’ for major depressive disorder [16]. The
authors found that psychodynamic therapy is more effective than
‘treatment as usual’ for depression [16]. However, the meta-
analysis did not include thorough assessment of bias risk in the
included trials, did not include trials using interpersonal
psychotherapy as experimental intervention, and did not employ
trial sequential analysis or other methods to reduce the risk of
random errors [17–19]. We therefore embarked on a systematic
review using Cochrane methodology to assess the effect of
interpersonal psychotherapy and other psychodynamic therapies
versus ‘treatment as usual’ [20]. We used assessment of bias risk to
reduce systematic errors [20], and trial sequential analysis to
reduce the risk of random errors [17–19].
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We conducted our systematic review of randomized clinical
trials involving meta-analysis [20] and trial sequential analysis
[18,19,21] to answer the question: what are the beneficial and
harmful effects of psychodynamic therapies versus ‘treatment as
usual’ in the treatment of major depressive disorder?
For details regarding the methodology please consult our
protocol published on our website (www.ctu.dk) in February 2010
before we began data extraction and analysis [22].
In short, we included all randomized clinical trials comparing
the effects of interpersonal psychotherapy or other psychodynamic
therapies versus ‘treatment as usual’ - irrespective of language,
publication status, publication year, and publication type based on
searches in The Cochrane Library’s CENTRAL, MEDLINE via
PubMed, EMBASE, Psychlit, Psyc Info, and Science Citation
Index Expanded. The timeframe for the search was all trials
published before February 2010.
To be included participants had to be older than 17 years with a
primary diagnosis of major depressive disorder. Trials were only
included if the diagnosis of depression was based on one of the
standardized criteria, such as DSM IV [23], ICD 10 [24], DSM
III [25], or DSM III-R [26].
Co-morbidity with other psychiatric diagnoses was not an
exclusion criterion. The following types of trials were excluded:
N Trials focusing on depressed participants with co-morbid
serious somatic illness, e.g., myocardial infarction, multiple
sclerosis, cerebral stroke, cancer, etc.
N Trials focusing on ‘late life’ depression or depression in the
elderly, most often participants over 65 years.
N Trials focusing on pregnancy-related depression, e.g., postpar-
tum depression, postnatal depression, etc.
N Drug or alcohol dependence-related depression.
These exclusions were conducted because we expect partici-
pants in such trials to respond differently to standardized
psychotherapy than other depressed patients, and these types of
depressed patients are traditionally examined in separate trials
[27–30].
Interventions
To be included the trials had to use at least one of the following
interventions:
N Trials using interpersonal psychotherapy [14,15].
N Psychotherapeutic methods based on one of the classic
developers of psychodynamic therapies such as Sifneos, Malan,
Mann, Davanloo, or Luborsky [31].
N The notions of transference and counter-transference (raising
awareness of the therapeutic relationship) [32].
Furthermore, the trials had to present a treatment manual and
had to document adherence to the treatment manual for the
interventions to be classified as ‘adequately defined’. All other
trials that used interventions classified as ‘interpersonal’, ‘psycho-
dynamic’, or ‘dynamic’ were included, but the interventions were
classified under ‘not adequately defined’.
For ‘treatment as usual’ control interventions we accepted any
non-specific treatments described as: ‘treatment as usual’,
‘standard care’, or ‘clinical management’. To be included the
‘treatment as usual’ condition had to include some kind of non-
specific supportive treatment.
Trials comparing psychodynamic therapies versus ‘treatment as
usual’ as add-on therapy to any co-intervention were included only
if these co-interventions were described and administered similarly
to the different intervention groups.
Two of the review authors (JJ and JLH) independently selected
relevant trials. If a trial only was identified by one of the two, it was
discussed whether the trial should be included. Excluded trials
were entered on a list, stating the reason for exclusion.
Data extraction
Data were extracted for trial design, bias risk, and outcomes
independently by two authors (JJ and JLH). Disagreements were
resolved by discussion or through arbitration (CG). We used the
instructions in The Cochrane Handbook for Systematic Reviews
of Interventions [20] in our evaluation of the methodology and
hence bias risk of the included trials. We assessed the bias risk in
respect to generation of the allocation sequence, allocation
concealment, blinding, intention-to-treat analysis, drop-outs,
reporting of outcome measures, economic bias, and academic
bias. These components enable classification of the included trials
into trials with ‘low risk of bias’ or with ‘high risk of bias’. The
trials were overall classified as ‘high risk of bias’ if one or more of
the above components was ‘uncertain’ or ‘high risk of bias’ [20,33–
36]. This classification is important because trials with ‘high risk of
bias’ may overestimate positive intervention effects and underes-
timate negative effects [20,33,34,36], and we wanted to relate the
validity of our results to the risk of bias in the included trials.
Primary outcome measures
Depressive symptoms. Our primary outcome was the
mean value of the Hamilton Rating Scale for Depression
(HDRS) [37], Becks Depression Inventory (BDI) [38], or
Montgomery-Asberg Depression Rating Scale (MADRS) [39] at
follow-up. We included data based on the total number of
randomized patients (intention-to-treat analysis) if these data were
reported. We planned to estimate the therapeutic follow-up
responses at two time points:
N At cessation of treatment: The trials original primary choice of
completion date was used. This was the most important
outcome measure time point in this review.
N At maximum follow-up.
Adverse events. We classified adverse events as serious or
non-serious. Serious adverse events were defined as medical events
that are life threatening; result in death; disability or significant loss
of function; that cause hospital admission or prolonged
hospitalization; a hereditary anomaly; or fetal injury [40]. All
other adverse events (that is, events that have not necessarily had a
causal relationship with the treatment, but that resulted in a
change in- or cessation of the treatment) were considered as non-
serious events.
Quality of life. We included any measure of quality of life,
noting each assessment measure.
Secondary outcome measures
Participants without remission. The proportion of
participants not having achieved remission. We included data
based on the total number of randomized participants (intention-
to-treat analysis) - if at all possible. If the results were not based on
the total number of participants, we preformed an intention-to-
treat analysis assuming that the participants not included in the
results did not achieve remission [20]. We pragmatically defined
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less than 10 [37–39].
Participants with suicidal inclination. Number of suicide
inclination, suicide attempts, or suicides.
Statistical methods
This meta-analysis was undertaken according to the recom-
mendations stated in The Cochrane Handbook for Systematic
Reviews of Interventions [20]. In analyzing continuous outcomes
with both fixed-effect and with random-effects models, we used the
mean difference (MD) with a 95% confidence interval. We used
RevMan version 5.0 [41]. We did not use ‘standardized mean
difference’ so each outcome measure was analyzed separately. We
did not adjust the outcome variables at follow-up according to the
baseline values [20].
We used the odds ratio with a 95% confidence interval to
estimate intervention effects on dichotomous outcomes with both
fixed-effect and with random-effects models [41].
For primary outcome measures, we also conducted trial
sequential analyses. In order to calculate the required information
size and the cumulative Z-curve’s eventual breach of relevant trial
sequential monitoring boundaries [17,18], the trial sequential
analysis was based on a type I error of 5%, a beta of 10% (power
of 90%), the variance of all the trials (as no trial had low risk of
bias), and a minimal relevant difference of 2 points on the HDRS.
Results
Search results
Our primary literature search identified 3212 publications.
According to our protocol [22] we excluded 3170 publications
either because they did not relate to psychodynamic therapies and
major depressive disorder, or because they were not randomized
trials comparing psychodynamic therapies versus ‘treatment as
usual’. 2831 of the 3170 were excluded on the basis of the title or
abstract and 339 of the 3170 were excluded on the basis of the full
publication.
Further 25 publications [42–66] were excluded because the trial
participants or the interventions did not meet our inclusion
criteria.
Included trials. We identified 17 publications [56–58,67–
80] on six trials [56,67,69,75,79,80], randomizing a total of 648
participants (Figure S1). The experimental interventions were by
the trialists classified as ‘interpersonal psychotherapy’ in five trials
[56,69,75,79,80] and as ‘psychodynamic psychotherapy’ in one
trial [67].
Only three of the trials [67,75,80] used an intervention that we
classified as ‘adequately defined’. We classified the therapists’ level
of experience and/or education one trial as ‘high’ [75], in two
trials as ‘intermediate’ [67,69], and in the last three as ‘unclear’
[56,79,80]. One trial used a combination of group therapy and
individual therapy [69], the remaining five used only individual
therapy [56,67,75,79,80].
The duration and the extend of the psychotherapy varied in the
different trials from five weeks of treatment [69] to 16 weekly
sessions followed by four monthly sessions [79].
The form and extend of the ‘treatment as usual’ interventions
varied greatly between all of the included trials (Table 1).
Two trials used antidepressants in both intervention groups
[67,69]. Burnand et al. used clomipramine [67] and Schramm et
al. used sertralin and amitriptyline [69]. The antidepressant
medicine was delivered similarly in the experimental and control
groups in both trials.
DiMascio et al. examined the effect of interpersonal psycho-
therapy versus ‘non-scheduled treatment’ [56]. The participants
were assessed with HDRS and The Raskin Depression Scale [81].
The results at end of treatment show a significant effect of
Interpersonal psychotherapy compared to ‘non- scheduled treat-
ment’, but no significant difference was found at one-year follow-
up. However, the trial did not report the SD for the mean values.
We have written to the authors requesting the necessary data - but
we have received no answer. Therefore, we have not been able to
include the results from this trial in the following analysis.
Table 1 summarizes the characteristics of the six included trials.
Bias risk. We assessed all six trials [56,67,69,75,79,80] as
having ‘high risk of bias’ due to unclear or inadequate components
as described in table 2.
Effects of psychodynamic therapy
Primary outcome measures. Five trials assessed HDRS as
a continuous outcome measure at the end of treatment
[67,69,75,79,80]. Three trials also assessed BDI [69,75,80].
HDRS. Meta-analysis with fixed-effect model on the HDRS
data from the five trials [67,69,75,79,80] shows that
psychodynamic therapies at cessation of treatment significantly
reduced depressive symptoms compared with ‘treatment as usual’.
We found a mean difference on -3.12 HDRS (95% CI 24.39 to
21.86; P,0.00001, I
2=0). The I
2 statistic describes the
percentage of variation across trials that are due to
heterogeneity rather than chance. Sub-analysis with fixed-effect
model on the HDRS-data from the four trials assessing
interpersonal psychotherapy [69,75,79,80] also showed a similar
reduction compared with ‘treatment as usual’ (P,0.00001).
However, the results from the one trial assessing psychodynamic
psychotherapy [82] did not show any significant difference in
effect (P=0.63) (Figure 1).
Two of the trials reported assessment data on the HDRS after
the cessation of treatment [69,80]. Schramm et al. assessed the
participants at 12 months after cessation of treatment [69]. Swartz
et al. assessed at nine months after the beginning of treatment [80].
Meta-analysis with fixed-effect model on these data showed a
mean difference on 24.61 HDRS (95% CI 26.98 to 22.24;
P,0.0001, I
2=0) in favor of psychodynamic therapies. Both trials
assessed interpersonal psychotherapy.
We performed a ‘test of interaction’ [83] to analyze if the effect
of two kinds of psychodynamic therapy differed between the three
trials assessing ‘interpersonal psychotherapy’ [69,75,79,80] and the
one trial assessing ‘short psychodynamic supportive psychothera-
py’ [67]. ‘Test of interaction’ showed no significant difference
(P=0.13), indicating that the effects of these two types of
psychodynamic therapy do not seem to differ.
Trial sequential analysis on the HDRS-data also showed a
significant beneficial effect of psychodynamic therapy compared
with ‘treatment as usual’ (figure 2).
BDI. Meta-analysis with fixed-effect model on the data from
the three trials [69,75,80] reporting results on the BDI at cessation
of treatment were in agreement with the results from the HDRS
(mean difference on 23.09 BDI (95% CI 25.35 to 20.83;
P=0.007, I
2=0). All three trials assessed interpersonal
psychotherapy.
Meta-analysis with fixed-effect model on the data from the two
trials [69,80] reporting results on the BDI at follow-up were in
agreement with the results from HDRS (mean difference on
25.54 BDI (95% CI 29.24 to 21.85; P=0.001, I
2=0).
Adverse events. Burnand et al. reported numbers of
hospitalizations, days of hospitalization, and lost workdays in the
different intervention groups [67]. They found significantly fewer
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non-significant higher tendency for participants in the ‘treatment
as usual’ group to be hospitalized after end of treatment [69].
Finally, DiMascio et al. included records on hospitalizations [56].
One participant in the experimental group and two in the control
group were hospitalized.
None of the remaining trials reported on adverse events.
Quality of life. None of the included trials assessed the effect
on quality of life of the participants.
Secondary outcome measures
Three trials [69,75,79] reported the proportion of participants
without remission as a dichotomous outcome measure. We had
planned to define remission as a Hamilton score of less than 8,
Table 1. Characteristics of the included trials.
Trials Participants (randomized) Interventions Outcomes & notes
DiMascio et al., 1979 48 Interpersonal psychotherapy (individual
16 weeks) versus supportive
psychotherapy ‘on demand’ (up to one
monthly session)
Raskin Depression Scale, HDRS
Elkin et al., 1989 125 Interpersonal psychotherapy (individual
16–20 weeks) versus pill-placebo and
clinical management (support,
encouragement and advice if necessary)
HDRS, BDI, remission HDRS (,7)
Schulberg et al., 1996 185 Interpersonal psychotherapy (16 weekly
individual sessions followed by 4 monthly
sessions) versus physicians usual care
(various procedures commonly used by
primary care physicians)
HDRS and remission HDRS (,8)
Burnand et al., 2002 90 Psychodynamic psychotherapy
(individual sessions for 10 weeks) and
125 mg clomipramine versus supportive
care (individual sessions for 10 weeks)
and 125 mg clomipramine
HDRS, days of hospitalization,
hospitalizations, lost work days, and
treatment failure (major depressive
disorder at 10 weeks)
Schramm et al., 2007 130 Interpersonal psychotherapy (individual
and group for 5 weeks) and
antidepressants (sertralin, amitriptyline)
versus clinical management (3 weekly
psychoeducative and supportive sessions
for 5 weeks) and antidepressants
(sertralin, amitrityline)
HDRS, BDI remission (HDRS ,8).
Participants were inpatients
Swartz et al., 2008 65 Interpersonal psychotherapy MOMS
(9 individual sessions) versus treatment
as usual (given referrals to mental health
clinics and told to seek treatment)
HDRS, BDI. IPT MOMS differs from
standardized IPT: shorter, brief behavioral
strategies, specific strategies to assist
mothers in managing psychiatrically ill
offspring
doi:10.1371/journal.pone.0019044.t001
Table 2. Risk of bias.
Allocation
sequence
generation?
Allocation
concealment?
Intention to
treat analysis?
Blinding of
outcome
assessors?
Comparability
of drop-outs
in intervention
groups?
Free of
selective
outcome
measure
reporting?
Free of
economic
bias?
Free of
academic
bias?
Overall
bias
assessment
DiMascio et al.,
1979
Unclear Unclear No Yes No Unclear Unclear Unclear High risk of
bias
Elkin et al., 1989 Unclear Unclear No Unclear No Yes Yes Unclear High risk of
bias
Schulberg et al.,
1996
Unclear Unclear Yes Yes Unclear Unclear Unclear Unclear High risk of
bias
Burnand et al.,
2002
Unclear Unclear No No Yes Unclear Unclear Unclear High risk of
bias
Schramm et al.,
2007
Yes Unclear No Yes Unclear Unclear Yes Unclear High risk of
bias
Swartz et al.,
2008
Unclear Unclear No Unclear Unclear Unclear Yes Unclear High risk of
bias
doi:10.1371/journal.pone.0019044.t002
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doi:10.1371/journal.pone.0019044.g001
Figure 2. Trial sequential analysis of the cumulative meta-analysis of the effect of psychodynamic therapies versus ‘treatment as
usual’ for major depressive disorder. The required information size of 2400 is calculated based on an intervention effect compared with
‘treatment as usual’, of 2 points on the HDRS, a variance of 228.4 on the mean difference, a risk of type I error of 5%, and a power of 90%. Even with
these presumptions, the cumulated Z-curve (blue curve) crosses the trial sequential monitoring boundaries (red inner sloping lines) implying that
there is firm evidence for a beneficial effect of psychodynamic therapies compared with ‘treatment as usual’.
doi:10.1371/journal.pone.0019044.g002
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possible, so we adopted the slightly different definitions of the
individual trials. Two trials defined remission as HRDS less than 8
[69,79]. One trial defined remission in two different ways: HDRS
less than 7 and BDI less than 10 [75]. In the latter trial the BDI
data showed no significant difference in remission between the two
intervention groups [75].
Meta-analysis on the HDRS-data from the three trials
[69,75,79] showed that psychodynamic therapy compared with
‘treatment as usual’ significantly decreases the risk of no remission
with an odds ratio of 0.36 (95% CI, 0.24 to 0.55; P=0.00001,
I
2=2%). The number needed to treat to obtain one extra patient
with remission is about four patients (95% CI, 3 to 8). All three
trials assessed interpersonal psychotherapy (Figure 3).
Only two of the trials [56,69] included records of suicide
attempts and suicides. Schramm et al. reported that one
participant initially treated with ‘standard care’ committed suicide
10 days after cessation of treatment [69]. No other participants
attempted suicide during the trial period. DiMascio et al. reported
that none of the participants had suicide attempts or committed
suicide during the trial period [56].
None of the trials reported on suicide inclination.
Random-effects model. None of our results were changed
noticeably by conducting random-effects model meta-analysis.
Subgroup analyses. In subgroup analyses of therapists’ level
of education and experience (high versus intermediate versus
unclear), type of therapy (group versus individual), and use of
antidepressants as co-intervention (antidepressant co-intervention
versus no antidepressant co-intervention), we found no
heterogeneity in our results. This indicates that these factors do
not seem to influence the effect of psychodynamic therapies.
We had also planned a subgroup-analysis according to risk of
bias [22]. However, as all trials were classified as ‘high risk of bias’
it was not possible to conduct this analysis.
Discussion
The results of our systematic review with meta-analysis and trial
sequential analysis show that randomized trials with low risk of
systematic errors (bias) and low risk of random errors (play of
chance) are needed. Psychodynamic therapies and especially
interpersonal psychotherapy might significantly reduce depressive
symptoms on the HDRS and increase the probability of remission
compared with ‘treatment as usual’, but due to the high risk of
systematic errors (bias) we cannot make any definite conclusions.
The possible benefit measured on the HDRS is presumably small.
The number needed to treat to obtain one extra patient with
remission may be about four patients. The impact of psychody-
namic therapies on suicidality, survival, and quality of life is
unknown.
It could be argued that interpersonal psychotherapy is not a
psychodynamic intervention. Interpersonal psychotherapy has its
theoretical roots in psychodynamic therapy but has integrated
elements from other therapies [14,15,84]. In spite of the
integrative content of interpersonal psychotherapy we chose, as
it’s often done in the literature, to classify interpersonal
psychotherapy as a form of psychodynamic therapy [14,85].
Furthermore, we believe that most forms of contemporary
psychodynamic therapies in practice are delivered in a way
similar to interpersonal psychotherapy.
Strengths
This review has a number of strengths. Our protocol was
published before we began systematic literature searches in all
relevant databases, data extraction, and data analyses. Data was
extracted by two independent authors minimizing the risk of
inaccurate data-extraction, and we assessed the risk of bias in all
trials according to the Cochrane Handbook guidelines [20]. We
meta-analyzed data both with fixed-effect and random-effects
models and both analyses were in agreement in all our results.
Furthermore, we performed trial sequential analysis to control for
random error [18,19,21]. The results of the trial sequential
analysis confirmed the cumulative meta-analysis result.
The characteristics of the participants in the different trials, as
well as the severity of the depressive symptoms differed. E.g., one
trial included only inpatients [69] and another trial included
depressed mothers whose children were receiving psychiatric
treatment [80]. Two of the trials used antidepressants as co-
intervention to psychodynamic therapies, and we included trials
both assessing interpersonal psychotherapy and psychodynamic
psychotherapy. Furthermore, the extent and form of the
‘treatment as usual’ condition varied greatly. We did not, however,
find any heterogeneity in our analyses and found no difference on
‘test of interaction’ between interpersonal psychotherapy and
psychodynamic psychotherapy. This indicates that there is a
comparable treatment effect between interpersonal psychotherapy
and other psychodynamic psychotherapies, between the different
forms of ‘treatment as usual’, and among the different populations
treated. This may make our results more generally applicable. On
the other hand, few trials with few participants were included and
only one trial used a psychodynamic intervention other than
interpersonal psychotherapy. This decreases our power to detect
any differences. Furthermore, in order to thoroughly examine a
difference in effect between two interventions head-to-head
comparisons are needed.
Limitations
Our systematic review has a number of limitations. Our results
are based on only six trials with a limited number of participants.
Also, all six trials had high risk of bias – so our results may be
Figure 3. Effect of interpersonal psychotherapy on remission. Events: participants not remitting.
doi:10.1371/journal.pone.0019044.g003
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classified as ‘adequately defined’, i.e., using and documenting the
use of a therapeutic manual. In clinical trials it is imperative that
the interventions are adequately defined and described [86].
Factors like personal style, communication skills, and personality
of the therapist evidently will influence the way psychotherapy is
delivered [87]. It is difficult to describe and control for these
subjective factors, and this makes it even more important to relate
the therapy to a treatment manual. Otherwise it is unclear what
kind of intervention the participants were receiving, and it is
difficult to apply any result in clinical practice. Moreover, a
number of subgroups of depressed patients were not included in
the trials of this review. These subgroups may react differently to
psychotherapy and of course our review cannot be generalized to
other than the included patient groups.
None of the trials reported measures of quality of life. Outcome
measures of quality of life are generally not standardized and
thoroughly individually validated [88]. The use of standardized
outcome measures for quality of life in research has been limited
by difficulties in administering and scoring quality of life [88], but
quality of life can be used as a valid outcome measure [35,88].
Typically, adverse events are not reported as thoroughly as
beneficial outcome measures [89], and only two of the included
trials included records of numbers of suicides and suicide attempts,
and only three trials reported on some adverse events. Some
psychological interventions might have harmful effects. Psycho-
logical debriefing for preventing post-traumatic stress disorder is
one example [90]. Debriefing has in some clinical trials showed to
have a harmful effect [90]. Possible harmful effects of this kind of
therapy are therefore not thoroughly examined.
Implications
Our results show that the possible benefit from this relatively
extensive treatment compared with ‘treatment as usual’ was only a
few points on the HDRS. From a clinical point of view it could be
argued that this possible benefit is not clinically relevant -
especially if you relate this mean difference to the extent and
length of the intervention. On the other hand, our analyses
demonstrate that the number needed to treat to obtain one extra
patient in remission was only about four patients. The latter
estimate was based on only two trials, which primarily defined
remission as Hamilton score under a given value.
The HDRS might not be a useful instrument to quantify the
effect of psychodynamic therapies. Other assessment methods
could demonstrate a more substantial effect of any given
intervention for depression. Furthermore, severity of depression
as measured by the total HDRS score has failed to predict suicide
attempts [91], and some publications have questioned the
usefulness of the HDRS and concluded that the scale is
psychometrically and conceptually flawed [92]. The two other
outcome measures often used to assess depressive symptoms,
MADRS and BDI, probably correspond to HDRS [93,94]. The
HDRS has during 40 years been the gold standard to quantify
depressive symptoms in clinical trials [92]. There may be a need
for other assessment methods.
A recently published meta-analysis examined the effect of short-
term psychodynamic psychotherapy for depression [16]. As
mentioned in the above, the meta-analysis did not include
thorough assessment of bias risk in the included trials, did not
include trials using interpersonal psychotherapy as experimental
intervention, and did not employ trial sequential analysis or other
methods to reduce the risk of random errors [17–19]. However,
the results showed a significant effect of short-term psychodynamic
psychotherapy on depressive symptoms and this result supports the
validity of our results in the present systematic review.
Future research should focus on comparing different forms of
manualized psychotherapy - or comparing psychodynamic
therapy with other treatments for depression. First and foremost
such trials should be conducted with low risk of bias and low risk of
random errors. Such trials should also report on adverse events,
suicide inclination, suicide attempts, and numbers of suicides.
There may be a need for a new gold standard assessment method
other than HRDS to assess depressive symptoms, and if possible
more effective interventions for depression must be developed.
Conclusions
Randomized trials with low risk of systematic errors (bias) and
low risk of random errors (play of chance) are needed.
Psychodynamic therapy, and especially interpersonal psychother-
apy, might be an effective intervention for major depressive
disorder compared with ‘treatment as usual’, but the possible
treatment effect measured on the HDRS is small. The impact of
psychodynamic therapies on suicidality, survival, and quality of life
is unknown.
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